
APPENDIX TABLES

#	Search	Results
1	"parkinson's disease" or "parkinson disease"	66099
2	limit 1 to randomized controlled trial	1407
3	2 and apomorphine	27
4	2 and rotigotine	17
5	2 and ropinirole	43
6	2 and pramipexole	61
7	2 and piribedil	12
8	2 and pergolide	25
9	2 and lisuride	14
10	2 and cabergoline	15
11	2 and bromocriptine	86
12	3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11	300

Table A Search Strategy utilized in MEDLINE

Trial	Weeks	11-16 weeks			Weeks	24-28 weeks		
		II	III	II+III		II	III	II+III
PD Grp. 2000 ¹	12	+	+	+	24	+	+	+
Rascol 2000 ²	12	+	+	+	24	+	+	+
Shannon 1997 ³	12	+	+	+	24	+	+	+
Kulisevsky 1998 ⁴	12	+	+	+	24	+	-	+
Barone 1999 ⁵	14	+	+	+	-	-	-	-
Barone 2010 ⁶	12	+	+	+	-	-	-	-
Wong 2003 ⁷	15	+	+	+	-	-	-	-
Kieburtz 2011 ⁸	12	+	+	+	-	-	-	-
Blindauer 2003 ⁹	11	+	+	-	-	-	-	-
Thomas 2006 ¹⁰	11	-	+	-	-	-	-	-
Poewe 2011 ¹¹	12	-	-	+	26	+	+	+
Sampaio 2011 ¹²	-	-	-	-	24	+	+	+
Singer 2007 ¹³	12	-	-	+	24	+	-	+
Watts 2010 ¹⁴	-	-	-	-	28	+	-	+
Giladi 2007 ¹⁵	-	-	-	-	24	+	+	+
Jankovic 2007 ¹⁶	12	-	-	+	28	+	-	+
Oertel 2006 ¹⁷	12	-	+	-	24	-	-	-
Hauser 2010 ¹⁸	11	-	+	+	-	-	-	-
Brooks 1998 ¹⁹	12	-	+	-	-	-	-	-
Whone 2003 ²⁰	12	-	+	-	24	-	+	-
Navan 2003 ²¹	12	-	+	-	-	-	-	-
Korczyn 1999 ²²	12	-	-	+	-	-	-	-
Mizuno 2013 ²³	12	+	+	+	-	-	-	-

Table B Early PD trials informing the respective time points and outcomes.

Trial	Weeks	11-16 weeks			24-28 weeks			
		II	III	'off'	Weeks	II	III	'off'
Schapira 2011 ²⁴	12	+	+	+	26	-	-	+
Mizuno 2003 ²⁵	12	+	+	-	-	-	-	-
Lieberman 1997 ²⁶	12	+	+	+	25	+	+	+
Poewe 2007 ²⁷	16	+	+	-	-	-	-	-
Pinter 1999 ²⁸	12	+	+	+	-	-	-	-
Hutton 1996 ²⁹	-	-	-	-	24	-	+	-
Mizuno 2007 ³⁰	12	+	+	+	-	-	-	-
Trenkwalder 2011 ³¹	12	+	+	-	-	-	-	-
Pahwa 2007 ³²	-	-	-	-	24	+	+	+
Barone 2007 ³³	-	-	-	-	26	+	+	+
Guttman 1997 ³⁴	-	-	-	+	24	+	+	+
Moller 2005 ³⁵	-	-	-	-	24	+	+	-
LeWitt 2007 ³⁶	-	-	-	-	24	+	+	+
Im 2003 ³⁷	12	-	+	+	-	-	-	-
Inzelberg 1996 ³⁸	-	-	-	-	24	-	+	+
Rektoreva 2003 ³⁹	-	-	-	-	24	-	+	-
Brunt 2002 ⁴⁰	-	-	-	-	24	-	+	-
Steiger 1996 ⁴¹	12	-	-	+	24	-	-	+
Koller 2001 ⁴²	12	-	-	+	-	-	-	-
Wermuth 1998 ⁴³	11	-	-	+	-	-	-	-
Rascol 1996 ⁴⁴	12	-	-	+	-	-	-	-
Lieberman 1998 ⁴⁵	-	-	-	-	24	-	-	+

Table C Advanced PD trials informing the respective time points and outcomes.

NR=Not reported; (+)=Only abstract publication available.

Early PD Patient Characteristics

Table D Characteristics of the randomized controlled trials of dopamine agonists included in the meta-analysis of early Parkinson's Disease

Trial	Arm	Dosage	Age mean (SD/range); *median	Male (%)	PD History (SD/ range); *median	Hoehn/Yahr Stage
Parkinson Study Group et al 2000 ¹	L-dopa/carbidopa	25/100mg tid	60.9(10.5)	66	1.8(1.7)	Stage I-II: 94% Stage III: 6%
	Pramipexole	0.5mg tid	61.5(10.1)	64	1.5(1.4)	Stage I-II: 97% Stage III: 3%
Rascol et al 2000 ²	L-dopa/benserazide	50-1200mg qd	63.0(9.0)	58	2.4(2.3)	Stage I-II: 90% Stage III: 10%
	Ropinirole	0.25-8mg tid	63.0(9.0)	63	2.5(2.8)	Stage I-II: 90% Stage III: 10%
Shannon et al 1997 ³	Placebo	NA	62.7	61	1.8	NA
	Pramipexole	0.375-4.5mg qd	62.7	61	1.8	NA
Kulisevsky et al 1998 ⁴	L-dopa/carbidopa	50/100-50/435mg qd	67.3	70	1.2(0.5)	Mean: 2
	Pergolide	0.05-3.0mg qd	63.7(10.5)	60	1.2(0.6)	Mean: 2
Barone et al 1999 ⁵	Placebo	NA	61.4(9.9)	69	NA	Mean: 2
	Pergolide	0.05-0.75mg qd	63.1(8.6)	57	NA	Mean: 2
Barone et al 2010 ⁶	Placebo	NA	67.4(9.0)	51	4.0(3.9)	Stage I-II: 84% Stage III: 16%
	Pramipexole	0.125-1.0mg qd	67.4(9.0)	43	4.0(4.5)	Stage I-II: 77% Stage III: 23%
Wong et al 2003 ⁷	Placebo	NA	60.9(9.7)	73	4.3(3.2)	Mean: 2
	Pramipexole	0.375-4.5mg qd	58.8(10.9)	66	4.5(3.4)	Mean: 2
Kieburtz et al 2011 ⁸	Placebo	NA	61.2(11.0)	75	2.8(2.3)	Stage I-II: 100% Stage III: 0%
	Pramipexole	0.5mg tid	62.1(10.2)	63	2.7(2.0)	Stage I-II: 100% Stage III: 0%
	Pramipexole	0.5mg bid	64.1(9.8)	71	2.5(1.8)	Stage I-II: 100% Stage III: 0%
	Pramipexole	0.75mg bid	63.9(9.9)	56	2.7(2.0)	Stage I-II: 100% Stage III: 0%
Blindauer et al 2003 ⁹	Placebo	NA	62.3(10.5)	49	1.3(1.4)	Stage I-II: 85% Stage III: 15%
	Rotigotine	4.5mg qd	61.8(9.8)	69	1.2(1.4)	Stage I-II: 94% Stage III: 6%
	Rotigotine	9.0mg qd	60.9(8.3)	77	1.5(2.0)	Stage I-II: 92% Stage III: 8%
	Rotigotine	13.5mg qd	61.3(10.9)	65	1.2(1.0)	Stage I-II: 92% Stage III: 8%
	Rotigotine	18.0mg qd	60.5(10.7)	59	1.1(1.2)	Stage I-II: 92% Stage III: 8%
Thomas et al 2006 ¹⁰	Ropinirole	15mg qd	55.3(2.0)	56	NA	Stage I-II: 100% Stage III: 0%
	Pramipexole	2.1mg qd	57.1(2.0)	56	NA	Stage I-II: 100% Stage III: 0%
Poewe et al 2011 ¹¹	Placebo	NA	62.0(9.6)	50	0.9(1.0)	Stage I: 29% Stage II-III: 71%
	Pramipexole(IR)	0.125-1.5mg tid	61.7(9.6)	57	1.1(1.4)	Stage I: 30% Stage II-III: 70%
	Pramipexole(ER)	0.375-4.5mg qd	61.3(9.8)	57	1.0(1.2)	Stage I: 34% Stage II-III: 66%

Sampaio et al 2011¹²	Placebo	NA	62.8(9.0)	63	0.8(0.9)	Stage I-II: 87% Stage III: 13%
	Pramipexole	1.5-4.5mg qd	60.8(11.7)	54	0.1(1.1)	Stage I-II: 88% Stage III: 12%
Singer et al 2007¹³	Placebo	NA	64.8(10.0)	61	1.4(1.9)	Mean: 2
	Ropinirole	0.75-24mg qd	65.4(11.4)	63	1.2(1.4)	Mean: 2
	Sumanidrol	1-16mg qd	63.4(9.1)	63	1.4(1.6)	Mean: 2
Watts et al 2010¹⁴	L-dopa/carbipoda	50-800mg qd	62.1(7.2)	71	2.7(2.4)	Mean: 2
	Ropinirole	2-24mg qd	61.4(7.0)	58	2.7(2.1)	Mean: 2
Giladi et al 2007¹⁵	Placebo	NA	60.1	58	1.2	Stage I-II: 85% Stage III: 15%
	Ropinirole	2-24mg qd	61.6	60	1.3	Stage I-II: 87% Stage III: 13%
	Rotigotine	2-8mg qd	61.1	55	1.4	Stage I-II: 79% Stage III: 21%
Jankovic et al 2007¹⁶	Placebo	NA	64.5(10.7)	60	1.4(1.3)	Stage I-II: 81% Stage III: 19%
	Rotigotine	4.5-13.5mg qd	62.0(10.3)	68	1.3(1.3)	Stage I-II: 81% Stage III: 19%
Oertel et al 2006¹⁷	L-dopa	50-150mg qd	59.1(9.5)	56	NA	Stage I-II: 100% Stage III: 0%
	Pergolide	0.05-0.75mg qd	58.8(9.3)	58	NA	Stage I-II: 100% Stage III: 0%
	Placebo	NA	63.2(8.7)	46	0.8(1.1)	Stage I: 28% Stage II-III: 72%
Hauser et al 2010¹⁸	Pramipexole (IR)	3.0mg qd	62.0(8.3)	57	0.9(1.2)	Stage I: 26% Stage II-III: 74%
	Pramipexole(ER)	3.0mg qd	61.6(9.4)	59	1.1(1.3)	Stage I: 29% Stage II-III: 71%
	Placebo	NA	57.0(36-72)*	64	2.2(0.4-6.4)*	Stage II: 64%
Brooks et al 1998¹⁹	Ropinirole	1-10mg qd	59.0(38-74)*	44	2.3(0.3-9.1)*	Stage II: 83%
	L-dopa/carbidopa	50-1000mg qd	59.9(9.2)	71	1.4(0.5)	Stage I-II: 100% Stage III: 0%
	Ropinirole	0.75-24mg qd	61.0(8.6)	64	1.3(0.6)	Stage I-II: 100% Stage III: 0%
Whone et al 2003²⁰	Placebo	NA	70.0(62-78)*	60	3.0(0.8-7)*	Mean: 1
	Pergolide	0.1-4.5mg qd	71.0(54-80)*	60	5.0(0.6-8)*	Mean: 1
	Pramipexole	0.125-4.5mg qd	66.0(55-80)*	70	4.0(0.5-10)*	Mean: 1
Korczyn et al 1999²²	Bromocriptine	1.25-24.1mg qd	62.7(10.4)	61	2.2(2.1)	Stage I-II: 91% Stage III: 9%
	Ropinirole	0.75-12.0mg qd	63.0(10.3)	61	1.9(1.8)	Stage I-II: 89% Stage III: 11%
	Placebo	NA	NA	42	1.8(1.9)	Stage II-III: 81%
Mizuno 2013²³	Rotigotine	2-16mg qd	NA	38	2.0(1.8)	Stage II-III: 77%

bid - twice daily; ER - extended-release; IR - immediate-release; PD - Parkinson's Disease; qd - once daily;
SD - standard deviation tid - three times daily

Advanced PD Patient Characteristics

Table E Characteristics of the randomized controlled trials of dopamine agonists included in the meta-analysis of advanced Parkinson's Disease

Trial	Arm	Dosage	Age mean (SD/range); *median	Male (%)	PD History (SD/range); *median	Hoehn/Yahr Stage
Schapira et al 2011 ²⁴	Placebo	NA	60.9(9.7)	52.8	5.9(3.8)	(Off) Stage IV-V: 14%
	Pramipexole (IR)	0.125-1.5mg tid	62.0(10.3)	56	6.6(4.4)	(Off) Stage IV-V: 20%
	Pramipexole (ER)	0.375-4.5mg qd	61.6(9.7)	56.1	6.1(4.0)	(Off) Stage IV-V: 12%
Mizuno et al 2003 ²⁵	Placebo	NA	64.0(8.6)	52.3	5.7(7.1)	Mean: 2.6(0.8)
	Bromocriptine	1.25-22.5mg qd	64.5(7.5)	47.1	5.0(4.0)	Mean: 2.6(0.7)
	Pramipexole	0.25-4.5mg qd	65.5(9.5)	58.8	4.8(4.1)	Mean: 2.7(0.7)
Lieberman et al 1997 ²⁶	Placebo	NA	63.3	64.8	9	Mean: 2.6
	Pramipexole	0.375-4.5mg qd	63.4	65.7	9.4	Mean: 2.6
Poewe et al 2007 ²⁷	Placebo	NA	65.0(10.0)	71	8.4(4.7)	NA
	Pramipexole	0.375-4.5mg qd	63.2(9.7)	56	8.4(4.7)	NA
Pinter et al 1999 ²⁸	Rotigotine	4-16mg qd	64.3(9.0)	66	8.9(4.4)	NA
	Placebo	NA	60.7(8.7)	70.5	8.5(5.2)	Stage >=II: 100%
	Pramipexole	0.2-5mg qd	59.3(8.3)	58.8	7.8(4.3)	Stage >=II: 100%
Hutton et al 1996 ²⁹	Placebo	NA	62.8(8.9)	64.6	10.5(5.0)	Mean: 2
	Cabergoline	0.5-5.0mg qd	63.4(10)	67.5	10.6(5.9)	Mean: 2
Mizuno et al 2007 ³⁰	Placebo	NA	64.7(9.3)	55.0	5.5(4.1)	Stage II-III: 95%
	Ropinirole	0.75mg qd	64.9(9.5)	56.2	5.5(3.7)	Stage II-III: 95%
Trenkwalder et al 2011 ³¹	Placebo	NA	64.4(10.6)	64.0	4.9(4.6)	NA
	Rotigotine	2-16mg qd	64.8(9.3)	64.0	4.6(4.2)	NA
Pahwa et al 2007 ³²	Placebo	NA	66.0(9.7)	67.9	8.6(5.2)	Mean: 2.7(0.6)
	Ropinirole	2-24mg qd	66.3(9.2)	58.2	8.6(4.8)	Mean: 2.7(0.5)
Barone et al 2007 ³³	Placebo	NA	65.1	61.5	6.1	Mean: 2.5
	Ropinirole	0.75-24mg qd	64.1	62.6	5.6	Mean: 2.6
Guttman et al 1997 ³⁴	Placebo	NA	63.7(10.4)	63.9	7.58(0.83-23)	(On) Stage II-V: 100%
	Bromocriptine	1.25-30mg qd	61.5(9.5)	65.5	7.17(1-23)	(On) Stage II-V: 100%
	Pramipexole	0.375-4.5mg qd	62.9(10.0)	60.8	6(0.67-36)	(On) Stage II-V: 100%
Moller et al 2005 ³⁵	Placebo	NA	64.7	67.8	7.9	(Off) Stage >=II: 98.9%
	Pramipexole	0.375-4.5mg qd	63.4	62.1	7.6	Stage >=II: 98.3%
LeWitt et al 2007 ³⁶	Placebo	NA	66.3(9.6)	61.7	7.7(4.0)	NA
	Rotigotine	8mg qd	66.5(10)	66.1	7.7(4.3)	NA
	Rotigotine	12mg qd	64.5(10.4)	64.0	7.8(4.6)	NA
Im et al 2003 ³⁷	Bromocriptine	1.25-17.5mg qd	60.0(8.3)	51.0	6.4(3.2)	Stage II-III: 97%
	Ropinirole	0.75-24mg qd	63.5(10.8)	57.0	6.8(3.8)	Stage II-III: 97%
Inzelberg et al 1996 ³⁸	Bromocriptine	5-40mg qd	71.0(8.0)	63.6	10.0(4.0)	(On) Stage II-III: 100%
	Cabergoline	0.25-6mg qd	71.0(8.0)	63.6	10.0(4.0)	(On) Stage II-III: 100%

Rektorova et al 2003³⁹	Pergolide	1.5-4.5mg qd	63.5(7.5)	61.0	NA	Mean: 3.0(1.0)
	Pramipexole	1.5-4.5mg qd	59.7(7.7)	61.0	NA	Mean: 2.8(0.8)
Brunt et al 2002a⁴⁰	Bromocriptine	4.5mg qd	65.1	75.0	9.5	Stage II-III: 82%
	Ropinirole	10mg qd	63.5	72.0	8.5	Stage II-III: 83%
Brunt et al 2002b⁴⁰	Bromocriptine	4.5mg qd	64.2	57.0	9.3	Stage II-III: 73%
	Ropinirole	10mg qd	63.5	66.0	9.0	Stage II-III: 74%
Steiger et al 1996⁴¹	Placebo	NA	63.4(7.2)	NA	11.9(5.4)	(Off) Mean: 3.5(1.4)
	Cabergoline	0.5-10mg qd	60.8(9.1)	NA	13.6(7.5)	(Off) Mean: 3.5(1.0)
Wermuth et al 1998⁴³	Placebo	NA	62.1(9.9)	60.6	9.9(4.1)	Stage II-III: 82%
	Pramipexole	0.2-5mg qd	63.2(7.9)	55.6	10.1(5.0)	Stage II-III: 92%
Rascol et al 1996⁴⁴	Placebo	NA	63.0(9.0)	60.9	8.0(3.0)	Stage I-III: 78%
	Ropinirole	1-8mg qd	62.0(7.0)	60.9	8.0(2.0)	Stage I-III: 82%
Lieberman et al 1998⁴⁵	Placebo	NA	NA	NA	9.4(6.3)	Stage II-III: 81%
	Ropinirole	0.75-24mg qd	NA	NA	8.6(4.7)	Stage II-III: 81%

bid - twice daily; ER - extended-release; IR - immediate-release; PD - Parkinson's Disease; qd - once daily;
SD - standard deviation tid - three times daily

Early PD Trial Intervention Characteristics

Table F Intervention characteristics of randomized controlled trials of dopamine agonists included in the meta-analysis of early Parkinson's Disease

Trial	Arm	Allowed Dosage	L-DOPA Dose mean (mg/d); *median	DA dose mean (mg/d); *median	% Patient on other active PD medication
Parkinson Study Group et al 2000¹	L-dopa/DDCI	25/100mg tid	509mg/d	509mg/d	Anticholinergics: 8% Amantadine: 22.7% L-Dopa: 20% Selegiline: 37.3%
	Pramipexole	0.5mg tid	264mg/d	2.78mg/d	Anticholinergics: 4.6% Amantadine: 20.5% L-Dopa: 26.5% Selegiline: 33.1%
Rascol et al 2000²	L-dopa/DDCI	50-1200mg qd	753mg/d	753mg/d	L-Dopa: 35%
	Ropinirole	0.25-8mg tid	753mg/d	16.5mg/d	L-Dopa: 52%
Shannon et al 1997³	Placebo	NA	NA	NA	Selegiline: ~66%
	Pramipexole	0.375-4.5mg qd	NA	3.8mg/d	Selegiline: ~66%
Kulisevsky et al 1998⁴	L-dopa/DDCI	50-100/435mg qd	435mg/d	435mg/d	NA
	Pergolide	0.05-3.0mg qd	435mg/d	2.8mg/d	NA
Barone et al 1999⁵	Placebo	NA	NA	NA	(L-Dopa, Amantadine, Selegiline, or Anticholinergics): 40.4%
	Pergolide	0.05-0.75mg qd	NA	2.06mg/d	(L-Dopa, Amantadine, Selegiline, or Anticholinergics): 34%
	Placebo	NA	NA	2.51mg/d	L-Dopa: 74% Amantadine: 22% MAO-B inhibitors: 13% Anticholinergics: 9% Dopaminergics: 6%
Barone et al 2010⁶	Placebo	NA	NA	NA	L-Dopa: 76% Amantadine: 25% MAO-B inhibitors: 13% Anticholinergics: 6% Dopaminergics: 5%
	Pramipexole	0.125-1.0mg qd	NA	2.18mg/d	Selegiline, Amantadine, Anticholinergics
Wong et al 2003⁷	Placebo	NA	NA	NA	Selegiline, Amantadine, Anticholinergics
	Pramipexole	0.375-4.5mg qd	NA	NA	MAO-B inhibitors, Anticholinergics, and Amantadine
Kieburtz et al 2011⁸	Placebo	NA	NA	NA	MAO-B inhibitors, Anticholinergics, and Amantadine
	Pramipexole	0.5mg tid	NA	1.5mg/d	MAO-B inhibitors, anticholinergics, and amantadine
	Pramipexole	0.5mg bid	NA	1.0mg/d	MAO-B inhibitors, anticholinergics, and amantadine
Blindauer et al 2003⁹	Pramipexole	0.75mg bid	NA	1.5mg/d	Anticholinergics: 23.4% Amantadine: 14.9% Selegiline: 14.9%
	Placebo	NA	NA	NA	

				Anticholinergics: 12.4% Amantadine: 18.0% Selegiline: 25.2%
	Rotigotine	4.5mg qd	NA	4.5mg/d*
	Rotigotine	9.0mg qd	NA	9.0mg/d*
	Rotigotine	13.5mg qd	NA	13.5mg/d*
	Rotigotine	18.0mg qd	NA	18.0mg/d*
Poewe et al 2011 ¹¹				(Anticholinergics, MAO-B inhibitors, Amantadine, Beta-blockers): 38.3
	Placebo	NA	NA	L-Dopa: 21.4%
	Pramipexole-IR	0.125-1.5mg tid	NA	(Anticholinergics, MAO-B inhibitors, Amantadine, Beta-blockers): 36.2%
	Pramipexole(ER)	0.375-4.5mg qd	NA	(Anticholinergics, MAO-B inhibitors, Amantadine, Beta-blockers): 40.8%
Sampaio et al 2011 ¹²				L-Dopa: 7%
	Placebo	NA	NA	Anticholinergics: 18.2% Amantadine: 27.3% Rasagiline: 2.7% Selegiline: 15.5%
	Pramipexole	1.5-4.5mg qd	NA	Anticholinergics: 20.9% Amantadine: 18.3% Rasagiline: 1.7% Selegiline: 19.1%
Singer et al 2007 ¹³	Placebo	NA	NA	Selegiline, Amantadine, Anticholinergics
	Ropinirole	0.75-24mg qd	NA	Selegiline, Amantadine, Anticholinergics
	Sumanireole	1-16mg qd	NA	Selegiline, Amantadine, Anticholinergics
Watts et al 2010 ¹⁴	L-dopa/DDCI	50-800mg qd	364mg/d	Selegiline, Amantadine, Anticholinergics, and Catechol-O- methyltransferase inhibitors
	Ropinirole	2-24mg qd	369mg/d	Selegiline, Amantadine, Anticholinergics, and Catechol-O- methyltransferase inhibitors
Giladi et al 2007 ¹⁵	Placebo	NA	NA	Selegiline, Amantadine, Anticholinergics
	Ropinirole	2-24mg qd	NA	Selegiline, Amantadine, Anticholinergics
	Rotigotine	2-8mg qd	NA	Selegiline, Amantadine, Anticholinergics
Jankovic et al 2007 ¹⁶	Placebo	NA	NA	Amantadine: 20% MAO-B Inhibitors: 15% Dopamine Agonists: 2% Anticholinergics: 7%
	Rotigotine	4.5-13.5mg qd	NA	Amantadine: 11% MAO-B Inhibitors: 12% Dopamine Agonists: <1% L-Dopa: 7%

Anticholinergics: 7%					
Oertel et al 2006¹⁷	L-dopa	50-150mg qd	504mg/d	504mg/d	Selegiline: 12.3%
	Pergolide	0.05-0.75mg qd	NA	3.23mg/d	Selegiline: 12.8%
Hauser et al 2010¹⁸	Placebo	NA	NA	NA	MAO-B Inhibitors, Amantadine, Anticholinergics
	Pramipexole (IR)	3.0mg qd	NA	NA	MAO-B Inhibitors, Amantadine, Anticholinergics
	Pramipexole(ER)	3.0mg qd	NA	NA	MAO-B Inhibitors, Amantadine, Anticholinergics
Brooks et al 1998¹⁹	Placebo	NA	NA	NA	NA
	Ropinirole	1-10mg qd	NA	NA	NA
Whone et al 2003²⁰	L-dopa/DDCI	50-1000mg qd	558.7mg/d	558.7mg/d	L-Dopa: 7.5%
	Ropinirole	0.75-24mg qd	NA	12.2mg/d	L-Dopa: 16%
Navan et al 2003²¹	Placebo	NA	635.4mg/d	NA	L-Dopa: 60% Amantadine: 10% Trihexyphenidyl: 20%
	Pergolide	0.1-4.5mg qd	635.4mg/d	NA	L-Dopa: 60% Amantadine: 10% Trihexyphenidyl: 20%
	Pramipexole	0.125-4.5mg qd	635.4mg/d	NA	L-Dopa: 60% Amantadine: 10% Trihexyphenidyl: 20%
	Bromocriptine	1.25-24.1mg qd	201.1mg/d	24.1mg/d	Selegiline: 34.1% Amantadine, Anticholinergics
Korcyn et al 1999²²	Ropinirole	0.75-12.0mg qd	223.1mg/d	12.0mg/d	Selegiline: 31.5% Amantadine, Anticholinergics
	Ropinirole	15mg qd	NA	15mg/d	Not Allowed
	Pramipexole	2.1mg qd	NA	2.1mg/d	Not Allowed
Mizuno et al 2013²³	Placebo	NA	0.0mg/d	NA	NA
	Rotigotine	2-16mg qd	0.0mg/d	NA	NA

bid - twice daily; ER - extended-release; IR - immediate-release; PD - Parkinson's Disease; qd - once daily; SD - standard deviation

tid - three times daily

Advanced PD Trial Intervention Characteristics

Table G Intervention characteristics of randomized controlled trials of dopamine agonists included in the meta-analysis of advanced Parkinson's Disease

Trial	Arm	Allowed Dosage	L-DOPA Dose mean (SD or range); *median	DA dose mean (SD or range); *median	% Patient receiving other medications
Schapira et al 2011 ²⁴	Placebo	NA	596.1mg/d	3.1mg/d	Amantadine: 28.7% MAO-B Inhibitors: 18% L-Dopa: 100% Entacapone: 7.3% Anticholinergics: 16.9%
	Pramipexole (IR)	0.125-1.5mg tid	619.1mg/d	2.8mg/d	Amantadine: 23.8% MAO-B Inhibitors: 14.6% L-Dopa: 100% Entacapone: 6.7% Anticholinergics: 14%
	Pramipexole (ER)	0.375-4.5mg qd	565.4mg/d	2.7mg/d	Amantadine: 26.9% MAO-B Inhibitors: 15.4% L-Dopa: 100% Entacapone: 9.7% Anticholinergics: 14.3%
Mizuno et al 2003 ²⁵	Placebo	NA	422.43mg/d	NA	L-Dopa: 100%
	Bromocriptine	1.25-22.5mg qd	377.88mg/d	17.75mg/d	L-Dopa: 100%
	Pramipexole	0.25-4.5mg qd	404.90mg/d	3.24mg/d	L-Dopa: 100%
Lieberman et al 1997 ²⁶	Placebo	NA	773.98mg/d	NA	L-Dopa: 100% Deprenyl: 52% Anticholinergics: 12%
	Pramipexole	0.375-4.5mg qd	633.89mg/d	NA	L-Dopa: 100% Deprenyl: 58% Anticholinergics: 14%
Poewe et al 2007 ²⁷	Placebo	NA	814mg/d	NA	L-Dopa: 94% Selegiline: 15% Anticholinergics: 10% Amantadine: 21% Entacapone: 12% Slow-Release L-Dopa: 22%
	Pramipexole	0.375-4.5mg qd	813mg/d	3.1mg/d	L-Dopa: 95% Selegiline: 20% Anticholinergics: 12% Amantadine: 17% Entacapone: 28% Slow-Release L-Dopa: 22%
Pinter et al 1999 ²⁸	Rotigotine	4-16mg qd	795mg/d	12.95mg/d	L-Dopa: 96% Selegiline: 14% Anticholinergics: 6% Amantadine: 18% Entacapone: 23% Slow-Release L-Dopa: 27%
	Placebo	NA	537.5mg/d	4.08mg/d	L-Dopa: 100% (MAO-B inhibitors, amantadine): 66%
	Pramipexole	0.2-5mg qd	592.6mg/d	3.59mg/d	L-Dopa: 100% (MAO-B inhibitors, amantadine): 73.6%
Hutton et al	Placebo	NA	NA	NA	L-Dopa: 100%

1996²⁹					Selegiline, Amantadine, Anticholinergics
					L-Dopa: 100%
	Cabergoline	0.5-5.0mg qd	NA	0.5-5.0mg/d	Selegiline, Amantadine, Anticholinergics
Mizuno et al 2007³⁰	Placebo	NA	319mg/d	NA	L-Dopa: 100%
	Ropinirole	0.75mg qd	325mg/d	7.12mg/d	L-Dopa: 100%
Trenkwalder et al 2011³¹					L-Dopa: 82% Anticholinergics, MAO-B inhibitors, NMDA Antagonists, Entacapone, L-Dopa: 81% Anticholinergics, MAO-B inhibitors, NMDA Antagonists, Entacapone,
	Placebo	NA	NA	NA	
	Rotigotine	2-16mg qd	NA	2-16mg/d	Antagonists, Entacapone,
Pahwa et al 2007³²	Placebo	NA	613mg/d	20mg/d	L-Dopa: 100%
	Ropinirole	2-24mg qd	546mg/d	18.8mg/d	L-Dopa: 100%
Barone et al 2007³³					L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
	Placebo	NA	618.1mg/d	NA	
	Ropinirole	0.75-24mg qd	663.1mg/d	18mg/d*	L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
Guttman et al 1997³⁴	Placebo	NA	NA	NA	L-Dopa: 100%
	Bromocriptine	1.25-30mg qd	NA	22.64mg/d	L-Dopa: 100%
	Pramipexole	0.375-4.5mg qd	NA	3.36mg/d	L-Dopa: 100%
Moller et al 2005³⁵					L-Dopa: 100% Deprenyl: 46.7% Anticholinergics: 26.1%
	Placebo	NA	648.8mg/d	NA	
	Pramipexole	0.375-4.5mg qd	637.7mg/d	3.7mg/d	L-Dopa: 100% Deprenyl: 47.1% Anticholinergics: 31.6%
LeWitt et al 2007³⁶	Placebo	NA	753mg/d	NA	L-Dopa: 100%
	Rotigotine	8mg qd	740mg/d	7.16mg/d	L-Dopa: 100%
	Rotigotine	12mg qd	760mg/d	9.51mg/d	L-Dopa: 100%
Im et al 2003³⁷					L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
	Bromocriptine	1.25-17.5mg qd	681.7mg/d	15.4mg/d	
	Ropinirole	0.75-24mg qd	711.1mg/d	7.9mg/d	L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
Inzelberg et al 1996³⁸	Bromocriptine	5-40mg qd	641mg/d	22.05mg/d	L-Dopa: 100%
	Cabergoline	0.25-6mg qd	608mg/d	3.18mg/d	L-Dopa: 100%
Rektorova et al 2003³⁹	Pergolide	1.5-4.5mg qd	491mg/d	3.0mg/d	L-Dopa: 100%
	Pramipexole	1.5-4.5mg qd	458mg/d	2.7mg/d	L-Dopa: 100%
Brunt et al 2002a⁴⁰					L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
	Bromocriptine	4.5mg qd	781mg/d	18mg/d	
	Ropinirole	10mg qd	730mg/d	10mg/d	L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
Brunt et al 2002b⁴⁰					L-Dopa: 100% Selegiline, Amantadine, Anticholinergics
	Bromocriptine	4.5mg qd	694mg/d	25mg/d	
	Ropinirole	10mg qd	662mg/d	14mg/d	L-Dopa: 100%

					Selegiline, Amantadine, Anticholinergics
Steiger et al 1996⁴¹	Placebo	NA	1092mg/d	NA	L-Dopa: 100%
	Cabergoline	0.5-10mg qd	706mg/d	5.4mg/d	L-Dopa: 100%
Koller et al 2001⁴²	Tolcapone	100-200mg tid	489.8mg/d	150mg/d	L-Dopa: 100%
	Pergolide	5mg qd	481.1mg/d	2.2mg/d	L-Dopa: 100%
Wermuth et al 1998⁴³	Placebo	NA	764.4mg/d	4.77mg/d	L-Dopa: 100% Amantadine, Anticholinergics
	Pramipexole	0.2-5mg qd	577.1mg/d	4.59mg/d	L-Dopa: 100% Amantadine, Anticholinergics
	Placebo	NA	NA	3.22mg/d	L-Dopa: 100% Selegiline: 7% Anticholinergics: 2% Amantadine
Rascol et al 1996⁴⁴	Ropinirole	1-8mg qd	NA	3.30mg/d	L-Dopa: 100% Selegiline: 5% Anticholinergics: 4% Amantadine
	Placebo	NA	792mg/d	NA	L-Dopa: 100% Selegiline: 55.6% Anticholinergics: 13% Amantadine: 11.1%
	Ropinirole	0.75-24mg qd	517mg/d	0.75-24mg/d	L-Dopa: 100% Selegiline: 50.5% Anticholinergics: 25.3% Amantadine: 15.8%

bid - twice daily; ER - extended-release; IR - immediate-release; PD - Parkinson's Disease; qd - once daily; SD - standard deviation tid - three times daily

References

1. Parkinson Study G. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. *JAMA : the journal of the American Medical Association*. Oct 18 2000;284(15):1931-1938.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *The New England journal of medicine*. May 18 2000;342(20):1484-1491.
3. Shannon KM, Bennett JP, Jr., Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. *Neurology*. Sep 1997;49(3):724-728.
4. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, Barbanoj M, Gironell A, Pascual-Sedano B. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. *Clinical neuropharmacology*. Nov-Dec 1998;21(6):358-362.
5. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. *Neurology*. Aug 11 1999;53(3):573-579.
6. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet neurology*. Jun 2010;9(6):573-580.

-
7. Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. *Journal of the neurological sciences*. Dec 15 2003;216(1):81-87.
 8. Kieburtz K, Parkinson Study Group Prami BIDI. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. *Movement disorders : official journal of the Movement Disorder Society*. Jan 2011;26(1):37-44.
 9. Parkinson Study G. A controlled trial of rotigotine monotherapy in early Parkinson's disease. *Archives of neurology*. Dec 2003;60(12):1721-1728.
 10. Thomas A, Bonanni L, Di Iorio A, et al. End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. *J Neurol*. Dec 2006;253(12):1633-1639.
 11. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. *Neurology*. Aug 23 2011;77(8):759-766.
 12. Sampaio C, Brzozova J, Hauser RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. *Movement disorders : official journal of the Movement Disorder Society*. Jul 2011;26(8):1464-1476.
 13. Singer C, Lamb J, Ellis A, Layton G, Sumanire for Early Parkinson's Disease Study G. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. Mar 15 2007;22(4):476-482.
 14. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. May 15 2010;25(7):858-866.
 15. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. *Movement disorders : official journal of the Movement Disorder Society*. Dec 2007;22(16):2398-2404.
 16. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. *Archives of neurology*. May 2007;64(5):676-682.
 17. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. *Movement disorders : official journal of the Movement Disorder Society*. Mar 2006;21(3):343-353.
 18. Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. Nov 15 2010;25(15):2542-2549.
 19. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. *Clinical neuropharmacology*. Mar-Apr 1998;21(2):101-107.
 20. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. *Annals of neurology*. Jul 2003;54(1):93-101.
 21. Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. Feb 2003;18(2):176-180.

-
22. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. *Neurology*. Jul 22 1999;53(2):364-370.
23. Mizuno Y, Nomoto M, Kondo T, et al. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial. *Movement disorders : official journal of the Movement Disorder Society*. Sep 2013;28(10):1447-1450.
24. Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. *Neurology*. Aug 23 2011;77(8):767-774.
25. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. Oct 2003;18(10):1149-1156.
26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. *Neurology*. Jul 1997;49(1):162-168.
27. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. *Lancet neurology*. Jun 2007;6(6):513-520.
28. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. *Journal of neurology, neurosurgery, and psychiatry*. Apr 1999;66(4):436-441.
29. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. *Neurology*. Apr 1996;46(4):1062-1065.
30. Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. *Movement disorders : official journal of the Movement Disorder Society*. Oct 15 2007;22(13):1860-1865.
31. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). *Movement disorders : official journal of the Movement Disorder Society*. Jan 2011;26(1):90-99.
32. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. *Neurology*. Apr 3 2007;68(14):1108-1115.
33. Barone P, Lamb J, Ellis A, Clarke Z. Sumanireole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. Mar 15 2007;22(4):483-489.
34. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. *Neurology*. Oct 1997;49(4):1060-1065.
35. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. *Movement disorders : official journal of the Movement Disorder Society*. May 2005;20(5):602-610.

-
- 36. LeWitt PA, Lyons KE, Pahwa R, Group SPS. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. *Neurology*. Apr 17 2007;68(16):1262-1267.
 - 37. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. *J Neurol*. Jan 2003;250(1):90-96.
 - 38. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. *Neurology*. Sep 1996;47(3):785-788.
 - 39. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. *European journal of neurology : the official journal of the European Federation of Neurological Societies*. Jul 2003;10(4):399-406.
 - 40. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, Study G. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. *Journal of neural transmission*. Apr 2002;109(4):489-502.
 - 41. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. *J Neurol*. Jan 1996;243(1):68-72.
 - 42. Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study G. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. *Movement disorders : official journal of the Movement Disorder Society*. Sep 2001;16(5):858-866.
 - 43. Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. *European journal of neurology : the official journal of the European Federation of Neurological Societies*. May 1998;5(3):235-242.
 - 44. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. *Clinical neuropharmacology*. Jun 1996;19(3):234-245.
 - 45. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. *Neurology*. Oct 1998;51(4):1057-1062.